Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis

Our study suggests oxaliplatin offers a survival advantage over MMC when used for HIPEC in CRC PC. Further studies to understand its efficacy, complications and ideal preparation are required. A Phase III randomised control trial comparing oxaliplatin and MMC would enhance decision-making.